Natco Pharma Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Natco Pharma has announced the results of its postal ballot (notice dated February 12, 2026), in which all four special resolutions for reappointment of directors were passed with overwhelming shareholder support. The reappointed directors, effective April 1, 2026, are: V.C. Nannapaneni as Chairman & Managing Director (98.74% in favour), Rajeev Nannapaneni as Vice Chairman & CEO (99.28% in favour), P.S.R.K. Prasad as Director & Executive VP – Corporate Engineering Services (99.40% in favour), and Dr. Donthineni Linga Rao as Director & President – Technical Affairs (99.40% in favour). E-voting ran from February 23 to March 24, 2026, with 62.16% of total shares (11.13 crore out of 17.91 crore) participating. The promoter group voted 100% in favour, while institutional holders voted 94–97% in favour and public retail holders voted over 99% in favour.
This is a routine governance update confirming continuity of top leadership through 2026. Very high approval across all categories signals strong shareholder confidence and no governance friction; unlikely to move the stock price meaningfully.